503b bulk list - Nexus Base

FDA to exclude semaglutide, tirzepatide and liraglutide on 503B bulks list — Photo by Nataliya Vaitkevich on Pexels

503b bulk list

20% Surge in Semaglutide Bills After FDA Excludes 503B

Semaglutide bills rose by about 20% after the FDA removed the drug from the 503B bulk list, and the price shock is now evident at the pharmacy counter. The rule change eliminates a key cost-saving pathway, pushing patients toward higher out-of-pocket expenses. I’ve been tracking these shifts for months,

FDA to exclude semaglutide, tirzepatide and liraglutide on 503B bulks list — Photo by Markus Spiske on Pexels

503b bulk list

Shows How FDA Exclusion Skews Semaglutide Supply

The FDA’s decision to remove semaglutide, tirzepatide and liraglutide from the 503B bulk list sharply reduces the supply chain for rural pharmacies, driving up prices and limiting patient access. Excluding these GLP-1 agents could cut a small town pharmacy’s revenue from GLP-1 drugs by nearly a third, according

503b bulk list

30% Revenue Cut When FDA Removes Semaglutide From 503B

The FDA’s decision has cut roughly 30% of revenue for many compounding pharmacies that depended on 503B bulk pricing for GLP-1 drugs. By removing semaglutide, tirzepatide and liraglutide from the bulk list, the agency has forced a sudden shift toward FDA-approved channels, tightening margins and raising compliance burdens. Medical

FDA Proposes to Exclude Semaglutide, Tirzepatide, Liraglutide From 503B Bulks List — Photo by Kampus Production on Pexels

503b bulk list

Semaglutide Exclusion Costs Rural Pharmacies 3 Critical Ways

The FDA’s move to pull semaglutide, tirzepatide and liraglutide from the 503B bulk list will raise prices for rural pharmacies, shrink drug availability and force clinics to renegotiate compounding contracts. 81% of small-company compounding pharmacies reported a 2% overhead reduction before the proposal, meaning the new direct fees are

FDA Proposes to Exclude Semaglutide, Tirzepatide, Liraglutide From 503B Bulks List — Photo by Markus Spiske on Pexels

503b bulk list

The Biggest Lie About Semaglutide 30% Cost Increase

A 15% price jump in semaglutide’s wholesale acquisition cost is often reported as a 30% increase, but the underlying driver is the FDA’s proposal to remove the drug from the 503B bulk list. The change reshapes how independent pharmacies obtain the medication and ripples through patient affordability. Medical